Salud financiera de hoja de balance de Myriad Genetics

Salud financiera controles de criterios 4/6

Myriad Genetics tiene un patrimonio de los accionistas total de $783.2M y una deuda total de $38.5M, lo que sitúa su ratio deuda-patrimonio en 4.9%. Sus activos y pasivos totales son $1.1B y $363.3M respectivamente.

Información clave

5.1%

Ratio deuda-patrimonio

US$38.70m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$104.30m
Patrimonio	US$760.00m
Total pasivo	US$350.50m
Activos totales	US$1.11b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($313.6M) de 0K3W superan a sus pasivos a corto plazo ($155.9M).

Pasivo a largo plazo: Los activos a corto plazo de 0K3W ($313.6M) superan a sus pasivos a largo plazo ($207.4M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 0K3W tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de 0K3W ha pasado de 25.7% a 4.9% en los últimos 5 años.

Cobertura de la deuda: El flujo de caja operativo de 0K3W es negativo, por lo que la deuda no está bien cubierta.

Cobertura de intereses: Datos insuficientes para determinar si los pagos de intereses de 0K3W sobre su deuda están bien cubiertos por el EBIT.

Salud financiera de hoja de balance de Myriad Genetics

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.67 loss in 1Q 2023)

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024

Full year 2023 earnings released: US$3.18 loss per share (vs US$1.39 loss in FY 2022)

New major risk - Revenue and earnings growth

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics.

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Insufficient new directors

Myriad Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $109.999996 million.

New minor risk - Shareholder dilution

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024

Third quarter 2023 earnings released: US$0.75 loss per share (vs US$0.43 loss in 3Q 2022)

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Insufficient new directors

Myriad Genetics Appoints Sam Raha as Chief Operating Officer, Effective December 11, 2023

Myriad Genetics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Bernstein Litowitz Berger & Grossmann LLP Proposes Settlement of Class Action Involving Persons Who Purchased or Acquired Myriad Genetics, Inc. Common Stock

Insufficient new directors

Myriad Genetics Announces Enhancements to the Genesight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$1.42 loss per share (vs US$0.17 loss in 2Q 2022)

Myriad Genetics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Myriad Genetics, Inc. Announces Inclusion of Breast Density to Myrisk(R) with Riskscore(R) Breast Cancer Risk Assessment

Myriad Genetics, Inc. Appoints Adam Brufsky as Scientific Advisor

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.26 loss in 1Q 2022)

Myriad Genetics, Inc. Revises Earnings Guidance for the Full Year of 2023

Full year 2022 earnings released: US$1.39 loss per share (vs US$0.35 loss in FY 2021)

High number of new directors

Myriad Genetics, Inc. Hires Senior Leaders to Advance Commercial Growth Plans

Myriad Genetics, Inc. announces Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

High number of new directors

Myriad Genetics Announces Urosuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-Driven Medical Information

Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.31 profit in 3Q 2021)

Myriad Genetics, Inc. (NasdaqGS:MYGN) acquired Gateway Genomics, LLC for approximately $110 million.

Myriad Genetics, Inc. Elects Paul M. Bisaro as New Board Member

High number of new directors

Myriad Genetics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

High number of new directors

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

High number of new directors

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2022

Myriad Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

High number of new directors

Myriad Genetics, Inc. Announces the Resignation of Dennis Langer as Director

High number of new directors

Myriad Genetics, Inc. Announces Executive Changes

High number of new directors

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

High number of new directors

Myriad Genetics, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Myriad Genetics, Inc., Annual General Meeting, Jun 02, 2022

Myriad Genetics, Inc. Settles the Qui Tam Lawsuit with STF, LLC

Forecast to breakeven in 2024

High number of new directors

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Myriad Genetics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Autoimmune’s Vectra Testing Business from Myriad Genetics, Inc. (NasdaqGS:MYGN).

Independent Chair of the Board recently sold US$627k worth of stock

Myriad Genetics, Inc. Reports Goodwill and Long-Lived Asset Impairment Charges for the Second Quarter Ended June 30, 2021

Myriad Genetics, Inc. Launches New Version of its MyRisk Hereditary Cancer Test

Q2 Solutions LLC completed the acquisition of Myriad RBM, Inc. from Myriad Genetics, Inc. (NasdaqGS:MYGN).

Q2 Solutions LLC signed a definitive agreement to acquire Myriad RBM, Inc. from Myriad Genetics, Inc. (NasdaqGS:MYGN) for approximately $200 million.

Myriad Genetics, Inc. to Share New Data at 2021 Asco Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

Myriad Genetics, Inc. Not to Provide Financial Guidance for the Quarter Ending June 30, 2021 or Fiscal Year 2021

Castle Biosciences, Inc. (NasdaqGM:CSTL) signed a definitive agreement to acquire Myriad myPath Melanoma, LLC from Myriad Genetics, Inc. (NasdaqGS:MYGN) for $32.5 million.

Castle Biosciences, Inc. (NasdaqGM:CSTL) signed a definitive agreement to acquire Myriad myPath, LLC from Myriad Genetics, Inc. (NasdaqGS:MYGN) for $32.5 million,

Bragar Eagel & Squire, P.C. Announces the Shareholder Class Action Against Myriad Genetics, Inc. Survives Motion to Dismiss and Encourages Long-term Investors to Contact the Firm